Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate
Para-chloro-2-[18F]Fluoroethyl-etomidate ([18F]CETO) as a New PET-tracer for Subtyping in Patients With Primary Aldosteronism - a Pilot Study
This study is trying to see if a special imaging technique can help doctors better understand different types of primary aldosteronism in patients.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 12 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Medical Center Groningen Academic / other |
| Locations | 1 site (Groningen, Provincie Groningen) |
| Trial ID | NCT06616142 on ClinicalTrials.gov |
What this trial studies
Processing failed - manual review needed
Who should consider this trial
Good fit: Unknown
Not a fit: Unknown
Why it matters
Potential benefit: Unknown
How similar studies have performed: Unknown
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * above 18 years * Biochemically established diagnosis of PA\* * Completion of standard diagnostic work-up of PA\* * Able to follow and understand instructions to participate in the study * Able to give written informed consent. Exclusion Criteria: * diabetes mellitus (i.e., HbA1c above 42 mmol/mol, and/or fasting plasma glucose \> 7.0 mol/l or non-fasting plasma glucose above 11.1 mmol/L ) * serious comorbidities precluding surgery * severe claustrophobia * pregnancy/breastfeeding or unable/unwilling to take adequate contraceptives (female only) * concurrent active infections (e.g., viral, fungal or parasite infections)\*\* * problematic venous access * unable/unwilling to take dexamethasone prior to \[18F\]CETO scanning * inability to temporary stop medication affecting aldosterone secretion * use of ketoconazole, metyrapone or cytostatic drugs during previous 6 months\*\*\* * long-term use of prednisolone and/or dexamethasone.
Where this trial is running
Groningen, Provincie Groningen
- University Medical Center Groningen — Groningen, Provincie Groningen, Netherlands (Recruiting)
Study contacts
- Principal investigator: Dr. M.N. Kerstens — Department of Internal Medicine - Endocrinology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
- Study coordinator: dr. M.N. Kerstens
- Email: m.n.kerstens@umcg.nl
- Phone: +31 0503613518
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions
Primary AldosteronismBilateral adrenal hyperplasiaPET/CT scan[18F]CETOAdrenal vein samplingPrimary aldosteronismAldosteron producing Adenoma
Last reviewed 2026-06-13 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.